 Shares of Global Blood Therapeutics Inc. GBT, 3.04 were up 34.4 in premarket trading on Thursday after Bloomberg reported that the company is attracting takeover interest, citing people familiar with the matter. Global Blood Therapeutics markets a treatment for sickle-cell disease called Oxbryta, which generated 194.7 million in revenue in 2021. 